Home 2017-10-03T09:13:29+00:00

Redbiotec, a Swiss biotechnology company, develops immunotherapies against Herpes and cancer.

Our therapies are based on best-in-class proteins and microorganisms.

Track record of Redbiotec in novel proteins:

  • Deals closed with pharma companies in U.S., Asia and Europe
  • Trade sale of spin-off Redvax to Pfizer (press release) for its CMV vaccine program
  • Internationally recognized scientists as scientific advisors
  • Engineering and production of >100 novel proteins and protein complexes
  • First company having successfully developed stable CMV pentamer at >95% purity